For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

Tesamorelin

Also known as: Egrifta

Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.

Real-time market data

Pricing for Tesamorelin

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Independent evidence

COAs for Tesamorelin

150 third-party tests across 28 vendors. Each card links to the full report.

All 150 COAs for Tesamorelin →
Measured purity 98.0%–100.0% across 81 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.26 %
Jun 2026
Janoshik Analytical

For

Tesamorelin

by Verified Peptides· batch TM07261020J

Aggregated · 3rd-party listing
99.00 %
May 2026
Ethos Analytics · HPLC

For

Tesamorelin

by OROS Research· batch OR-LPTES5-526-B6

Aggregated · 3rd-party listing
99.77 %
May 2026
ILS Labs · HPLC

For

Tesamorelin

by Glacier Aminos· batch TES10GA-07

Aggregated · 3rd-party listing
99.47 %
May 2026
ILS Labs · HPLC

For

Tesamorelin

by Crush Research· batch CR-TSM20-0307-1

Aggregated · 3rd-party listing
99.24 %
May 2026
Janoshik Analytical · HPLC

For

Tesamorelin

by Skye Peptides· batch TESA26-10-002

Aggregated · 3rd-party listing
99.23 %
May 2026
Janoshik Analytical · HPLC

For

Tesamorelin

by Skye Peptides· batch TESA26-20-004

Aggregated · 3rd-party listing
99.48 %
May 2026
ILS Labs

For

Tesamorelin

by NG Peptide· batch TSM20-3

Aggregated · 3rd-party listing
99.78 %
May 2026
ILS Labs

For

Tesamorelin

by Ion Peptide· batch TSM10-05042026

Aggregated · 3rd-party listing
99.74 %
May 2026
MDx BioAnalytical Laboratory

For

Tesamorelin

by BioLongevity Labs· batch 28-3-46149

Aggregated · 3rd-party listing
99.77 %
Apr 2026
MDx BioAnalytical Laboratory · HPLC

For

Tesamorelin

by BioLongevity Labs· batch 28-3-46136

Aggregated · 3rd-party listing
99.68 %
Apr 2026
Janoshik Analytical

For

Tesamorelin

by NG Peptide· batch TSM10-13

Aggregated · 3rd-party listing
99.73 %
Apr 2026
ILS Labs

For

Tesamorelin

by Riptide Wellness· batch RWTES-10-1004

Aggregated · 3rd-party listing
99.84 %
Apr 2026
Janoshik Analytical

For

Tesamorelin

by Reta Peptide· batch 20260409

Aggregated · 3rd-party listing
99.40 %
Apr 2026
ILS Labs

For

Tesamorelin

by NG Peptide· batch TSM11

Aggregated · 3rd-party listing
99.74 %
Apr 2026
Janoshik Analytical · HPLC

For

Tesamorelin

by Peptidegurus· batch cmojgr3yn00259grxv12jfffy

Aggregated · 3rd-party listing
99.91 %
Apr 2026
Freedom Diagnostics · HPLC

For

Tesamorelin

by Peptide Tech· batch TSG-8475

Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics · HPLC

For

Tesamorelin

by OROS Research· batch OR-LPTES5-326-B5

Aggregated · 3rd-party listing
99.95 %
Apr 2026
Kovera Labs

For

Tesamorelin

by Ion Peptide· batch TSM10-04042026

Aggregated · 3rd-party listing
99.79 %
Apr 2026
Janoshik Analytical · HPLC

For

Tesamorelin

by Verified Peptides· batch cmojb57tr00tskirxbkigs5iy

Aggregated · 3rd-party listing
99.08 %
Apr 2026
Freedom Diagnostics · HPLC

For

Tesamorelin

by Blank Peptides· batch 665394

Aggregated · 3rd-party listing
99.50 %
Mar 2026
Janoshik Analytical · HPLC

For

Tesamorelin

by Skye Peptides· batch TESA26-20-003

Aggregated · 3rd-party listing
99.11 %
Mar 2026
Freedom Diagnostics · HPLC

For

Tesamorelin

by Forge Performance Co.· batch Clear Red Cap

Aggregated · 3rd-party listing
99.74 %
Mar 2026
Janoshik Analytical · HPLC

For

Tesamorelin

by Skye Peptides· batch TESA26-20-002

Aggregated · 3rd-party listing
99.16 %
Mar 2026
Freedom Diagnostics · HPLC

For

Tesamorelin

by Simple Peptide· batch TESM-032026-1

Research depth

30 citations indexed for Tesamorelin

All research on Tesamorelin →

case-report · 2026

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists

Background Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI).

review · 2026

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials

Background HIV-associated lipodystrophy leads to visceral fat accumulation, metabolic complications, body image concerns, medication non-adherence, and increased cardiovascular risks.

animal · 2026

Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant deleterious electrocardiographic changes in a rodent model

The introduction of combination antiretroviral therapy (cART) has significantly reduced AIDS-related morbidity and mortality. However, the prevalence of age-associated comorbidities, particularly cardiovascular diseases (CVD), has increased, becoming a leading cause of mortality in people living with HIV.

Study · 2026

P-1230. Tesamorelin (EGRIFTA WR and EGRIFTA®) Formulations: Bioequivalence in Healthy Participants

Study · 2026

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.

Study · 2026

Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance

Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration.